Skip to main content
VRPX logo

Virpax Pharmaceuticals, Inc. (VRPX) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.002 $0.00 (0.00%)
Vol: 51| 52-wk range: $0.0001 – $0.10

Beta 2.01: the stock has moved about 101% more than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Virpax Pharmaceuticals, Inc. (VRPX) trades at $0.002. Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company focused on developing non-opioid pain management and CNS disorder treatments. Their pipeline includes drug-delivery systems like Epoladerm, Probudur, and Envelta. Sector: Healthcare.

Price as of · Last analyzed: Mar 16, 2026
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company focused on developing non-opioid pain management and CNS disorder treatments. Their pipeline includes drug-delivery systems like Epoladerm, Probudur, and Envelta.

Analyst Coverage for VRPX: VRPX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • AKTX · Akari Therapeutics, Plc · 29 /100
  • PIII · P3 Health Partners Inc. · 31 /100
  • RLYB · Rallybio Corporation · 82 /100

See all scored stocks →

Virpax Pharmaceuticals, Inc. (VRPX) Healthcare & Pipeline Overview

CEOJatinder Dhaliwal
Employees2
HeadquartersBerwyn, US
IPO Year2021

Virpax Pharmaceuticals, Inc., a preclinical-stage biotech firm, specializes in innovative drug-delivery systems targeting non-opioid pain management and central nervous system disorders. Their pipeline features novel technologies like topical NSAIDs, injectable liposomal gels, and nanotechnology-based intranasal sprays, positioning them in the evolving pharmaceutical landscape.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 16, 2026

What Is the Investment Thesis for VRPX?

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Virpax Pharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity characteristic of preclinical-stage biotechnology companies. The company's value hinges on the successful development and commercialization of its drug-delivery technologies. Key value drivers include the progression of Epoladerm, Probudur, and Envelta through clinical trials, with positive data readouts serving as major catalysts. Given the company's small size and limited resources (2 employees), strategic partnerships and collaborations will be crucial for advancing its pipeline. The company's beta of 2.01 indicates high volatility. The lack of revenue and a negative P/E ratio of -0.01 reflect its preclinical status. Successful navigation of regulatory hurdles and demonstration of clinical efficacy are essential for realizing the potential of Virpax's innovative drug delivery systems.

Based on FMP financials and quantitative analysis

VRPX Key Highlights

AI-written as of Mar 16, 2026 — figures and tone reflect the data available then, not today's score.

Virpax Pharmaceuticals is a preclinical-stage company, indicating high potential but also significant risk.

  • The company focuses on non-opioid pain management, aligning with current healthcare trends and regulatory pressures to reduce opioid use.
  • Virpax's pipeline includes multiple drug-delivery systems, diversifying its risk but also requiring significant capital investment.
  • The company's small size (2 employees) suggests a reliance on outsourcing and partnerships for development and commercialization.
  • The company has a beta of 2.01, indicating high volatility compared to the broader market.

Who Are VRPX's Competitors?

VRPX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
AKTX Akari Therapeutics, Plc $6.71 -2.47% $15.3M —
PIII P3 Health Partners Inc. $1.86 -13.49% $385M 31 5-pillar
RLYB Rallybio Corporation $15.26 -0.20% $85.5M 82 5-pillar
ICCC ImmuCell Corporation $11.25 -0.71% $102M 82 5-pillar
ORMP Oramed Pharmaceuticals Inc. $3.89 +0.52% $169M 72 5-pillar
CGEN Compugen Ltd. $1.88 -4.08% $178M 69 5-pillar
PLX Protalix BioTherapeutics, Inc. $3.06 +1.32% $258M 90 5-pillar
FENC Fennec Pharmaceuticals Inc. $13.33 -1.84% $471M 91 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VRPX's Key Strengths?

Innovative drug-delivery technologies.

  • Focus on non-opioid pain management.
  • Novel intranasal drug delivery system for targeting the brain.
  • Diverse pipeline of preclinical-stage product candidates.

What Are VRPX's Weaknesses?

Preclinical-stage company with no approved products.

  • Limited financial resources.
  • Small team size (2 employees).
  • High reliance on outsourcing and partnerships.

What Are the Key Risks for VRPX?

Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

  • Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
  • Failure to secure funding for clinical trials.
  • Negative results from clinical trials.
  • Regulatory delays or rejection of product candidates.
  • Competition from established pharmaceutical companies.
  • Dependence on third-party manufacturers and suppliers.

What Threats Does VRPX Face?

  • Regulatory hurdles and clinical trial failures.
  • Competition from established pharmaceutical companies.
  • Patent infringement and intellectual property disputes.
  • Economic downturn and reduced healthcare spending.

What Are VRPX's Competitive Advantages?

  • Proprietary drug-delivery technologies protected by patents.
  • Focus on non-opioid pain management, addressing a growing market need.
  • Novel intranasal drug delivery system for targeting the brain.
  • Pipeline of preclinical-stage product candidates with diverse applications.

What Does VRPX Do?

Founded in 2016 and headquartered in Berwyn, Pennsylvania, Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company dedicated to developing innovative drug-delivery systems and drug-releasing technologies. The company's primary focus is on advancing non-opioid and non-addictive pain management treatments, as well as treatments for central nervous system (CNS) disorders. Virpax's approach centers around creating novel formulations and delivery methods to improve drug efficacy, reduce side effects, and enhance patient outcomes. Virpax's pipeline consists of several preclinical-stage product candidates. Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID), is being developed for the treatment of chronic osteoarthritis of the knee. Probudur is an injectable local anesthetic liposomal gel technology designed for postoperative pain management, aiming to provide sustained pain relief and reduce the need for opioid analgesics. Envelta, a nanotechnology-based intranasal spray, is designed to deliver metabolically labile peptide drugs directly into the brain, potentially offering a non-invasive treatment option for various CNS conditions. Other product candidates include PES200, another technology for delivering peptide drugs to the brain; AnQlar, an anti-viral barrier intended to prevent or reduce the risk and intensity of viral infections, including influenza and SARS-CoV-2; and VRP324, an investigational formulation for nasal delivery to enhance cannabidiol transport to the brain. These diverse programs reflect Virpax's commitment to addressing unmet medical needs through innovative drug delivery solutions.

What Products and Services Does VRPX Offer?

  • Develop drug-delivery systems for non-opioid pain management.
  • Create drug-releasing technologies for central nervous system disorders.
  • Formulate topical nonsteroidal anti-inflammatory drugs (NSAIDs) for osteoarthritis.
  • Design injectable local anesthetic liposomal gels for postoperative pain.
  • Utilize nanotechnology-based intranasal sprays for drug delivery to the brain.
  • Develop anti-viral barriers to prevent or reduce the risk of viral infections.
  • Create nasal formulations to enhance cannabidiol transport to the brain.

How Does VRPX Make Money?

  • Develop and patent novel drug-delivery technologies.
  • Outsource manufacturing and clinical trials.
  • Seek partnerships with larger pharmaceutical companies for commercialization.
  • Generate revenue through licensing agreements and royalties.

What Industry Does VRPX Operate In?

The biotechnology industry is characterized by intense competition, high R&D costs, and a lengthy regulatory approval process. Virpax Pharmaceuticals operates within this landscape, focusing on innovative drug-delivery systems to differentiate itself. The market for non-opioid pain management is growing due to concerns about opioid addiction, creating an opportunity for Virpax's Epoladerm and Probudur. Similarly, the market for CNS disorder treatments is expanding, driven by an aging population and increasing prevalence of neurological conditions. Competitors include companies like ACON, AKTX, DRMA, FOXO, and PIII, some of whom are also developing novel drug delivery systems.

Who Are VRPX's Key Customers?

  • Pharmaceutical companies seeking innovative drug-delivery technologies.
  • Patients suffering from chronic pain and central nervous system disorders.
  • Healthcare providers looking for non-opioid pain management solutions.
  • Individuals seeking preventative measures against viral infections.
Model self-rating on this text: 69% (not a measure of the evidence) Updated: Mar 16, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage

Company Profile

Virpax Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Berwyn, US. The company is led by CEO Jatinder Dhaliwal. VRPX has traded publicly since 2021.

F-Score 0/9

Financial Health

Virpax Pharmaceuticals, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

3/8 beats

Earnings Track Record

Virpax Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 106.1% below estimates on average.

FY2026 est

Forward Outlook

Wall Street analysts project Virpax Pharmaceuticals, Inc. revenue of about $0 for fiscal 2026, with EPS near $-12.50.

VRPX Latest News

No recent news available for VRPX.

VRPX Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VRPX.

Price Targets

Wall Street price target analysis for VRPX.

VRPX MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VRPX; grades run from A+ (80-100) to F (below 30).

Leadership: Jatinder Dhaliwal

CEO

Jatinder Dhaliwal serves as the Chief Executive Officer of Virpax Pharmaceuticals, Inc. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. He has held various leadership positions in companies focused on developing innovative therapies. Dhaliwal's expertise encompasses strategic planning, business development, and financial management. His educational background includes advanced degrees in science and business administration, providing him with a strong foundation for leading a biotechnology company.

Track Record: Under Jatinder Dhaliwal's leadership, Virpax Pharmaceuticals has focused on advancing its pipeline of preclinical-stage product candidates. Key milestones include the development of novel drug-delivery systems and the progression of Epoladerm, Probudur, and Envelta towards clinical trials. Dhaliwal has also focused on securing intellectual property protection for the company's technologies and building strategic partnerships to support its growth.

VRPX OTC Market Information

VRPX trades on the OTC Other market tier of OTC Markets.

  • OTC Tier: OTC Other

Common Questions About VRPX (Healthcare)

What are the main risks for VRPX?

The main risks for Virpax Pharmaceuticals, Inc. include the challenges inherent in developing and commercializing new pharmaceutical products. Clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies pose significant threats. Dependence on third-party manufacturers and suppliers adds another layer of risk.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on publicly available sources and may be subject to change.
  • Preclinical-stage companies are inherently risky investments.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives